Merck Urges Justices To Save Historic $2.5B Patent Verdict
A Merck & Co. unit has asked the U.S. Supreme Court to answer key questions related to whether a hepatitis C treatment patent is invalid in hopes of reviving a $2.54...To view the full article, register now.
Already a subscriber? Click here to view full article